

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7099417

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
MAIKO HAMADA	11/24/2021
YUKI ARAI	11/25/2021
SHUHEI YAMAKOSHI	11/24/2021
HIROKO WADA	11/24/2021
KAZUFUMI OTSUKI	11/18/2021
HIROAKI SHITAMA	11/18/2021
NOBUYUKI TAKAKURA	12/01/2021
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	MITSUBISHI TANABE PHARMA CORPORATION
<b>Street Address:</b>	3-2-10, DOSHO-MACHI, CHUO-KU
<b>City:</b>	OSAKA-SHI, OSAKA
<b>State/Country:</b>	JAPAN
<b>Postal Code:</b>	541-8505
<b>Name:</b>	OSAKA UNIVERSITY
<b>Street Address:</b>	1-1, YAMADAOKA
<b>City:</b>	SUITA-SHI, OSAKA
<b>State/Country:</b>	JAPAN
<b>Postal Code:</b>	565-0871
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17518212
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(312)616-5700
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	3126165600
<b>Email:</b>	arosales@leydig.com
<b>Correspondent Name:</b>	LEYDIG, VOIT & MAYER, LTD.
<b>Address Line 1:</b>	TWO PRUDENTIAL PLAZA, SUITE 4900
<b>Address Line 2:</b>	180 N. STETSON AVE.

PATENT

<b>Address Line 4:</b> CHICAGO, ILLINOIS 60601-6745	
<b>ATTORNEY DOCKET NUMBER:</b>	758140
<b>NAME OF SUBMITTER:</b>	JOHN KILYK, JR.
<b>SIGNATURE:</b>	/John Kilyk, Jr./
<b>DATE SIGNED:</b>	12/30/2021
<b>Total Attachments: 11</b> source=Assignment#page1.tif source=Assignment#page2.tif source=Assignment#page3.tif source=Assignment#page4.tif source=Assignment#page5.tif source=Assignment#page6.tif source=Assignment#page7.tif source=Assignment#page8.tif source=Assignment#page9.tif source=Assignment#page10.tif source=Assignment#page11.tif	

**ASSIGNMENT**

**WHEREAS, I/We**

(1) Maiko HAMADA of c/o MITSUBISHI TANABE PHARMA CORPORATION,  
3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan,

(2) Yuki ARAI of c/o MITSUBISHI TANABE PHARMA CORPORATION, 3-2-10,  
Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan,

(3) Shuhei YAMAKOSHI of c/o MITSUBISHI TANABE PHARMA  
CORPORATION, 3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan,

(4) Hiroko WADA of c/o MITSUBISHI TANABE PHARMA CORPORATION, 3-2-  
10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan,

(5) Kazufumi OTSUKI of c/o MITSUBISHI TANABE PHARMA CORPORATION,  
3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan,

(6) Hiroaki SHITAMA of c/o MITSUBISHI TANABE PHARMA CORPORATION,  
3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan, and

(7) Nobuyuki TAKAKURA of c/o OSAKA UNIVERSITY, 1-1, Yamadaoka, Suita-  
shi, Osaka 565-0871 Japan,

hereinafter referred to as Assignor, have invented a certain invention entitled:

**NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE**

for which invention an application (provisional or non-provisional) for a U.S. patent was filed  
on November 3, 2021, under U.S. Application No. 17/518,212, and

**WHEREAS,**

MITSUBISHI TANABE PHARMA CORPORATION, 3-2-10, Dosho-machi, Chuo-  
ku, Osaka-shi, Osaka 541-8505 Japan, and

OSAKA UNIVERSITY, of 1-1, Yamadaoka, Suita-shi, Osaka 565-0871 Japan,

hereinafter referred to as Assignee, is desirous of acquiring the entire U.S. right, title,  
and interest of Assignor in, to, and under the invention and the referenced International Patent  
Application, including the entire right, title, and interest of Assignor in, to, and under the U.S.  
national phase thereof, filed on November 3, 2021 as U.S. Patent Application No. 17/518,212,

**NOW, THEREFORE,** for good and valuable consideration, the receipt and sufficiency of  
which is hereby acknowledged,

Assignor assigns and transfers to Assignee the entire U.S. right, title, and interest of Assignor in, to, and under the invention, the referenced International Patent Application and U.S. national phase thereof, and other such U.S. patent applications (e.g., continuations, continuations-in-part, divisionals, reissues, and reexaminations) that may be filed in the U.S. with a claim of priority to the referenced International Patent Application and/or the U.S. national phase application thereof, as well as U.S. patents that may issue thereon and that may be modified as the result of applicable procedures (e.g., supplemental examinations, ex parte reexaminations, inter partes reexaminations, inter partes reviews, and post-grant reviews),

Assignor conveys to the Assignee the right to make applications in Assignee's own behalf for protection of the invention in the U.S. and to claim priority in the U.S. to the aforementioned patent applications and any priority documents referenced therein under the Patent Cooperation Treaty, the Paris Convention, and any other international arrangements,

Assignor will not execute any writing or do any act conflicting with the terms of this assignment,

Assignor will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to pursue the U.S. patent applications identified herein, including, but not limited to, rendering all necessary assistance in making applications for and obtaining patents that may issue thereon in the U.S. on the invention, and in enforcing any rights accruing as a result of such U.S. applications or patents, by, for example, executing statements and other affidavits,

Assignor and Assignee agree the terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,

Assignor authorizes Assignee to insert in this assignment the number and filing date of the U.S. patent application if the number and filing date of the U.S. patent application are not recited herein at the time of execution of this assignment by any or all of the parties hereto,

Assignor and Assignee agree that U.S. law governs this assignment, and

Assignee acknowledges and accepts this assignment.

IN WITNESS WHEREOF, Assignor has hereunder set his/her hand on the date shown below.

Date 2021 / 11 / 24

Maiko HAMADA

Assignor: Maiko HAMADA

Assignment

Attorney Docket No. 758140

Client Reference No. 203636

Date 2021/11/25

Yuki ARAI

Assignor: Yuki ARAI

Date \_\_\_\_\_

\_\_\_\_\_

Assignor: Shuhei YAMAKOSHI

Date \_\_\_\_\_

\_\_\_\_\_

Assignor: Hiroko WADA

Date \_\_\_\_\_

\_\_\_\_\_

Assignor: Kazufumi OTSUKI

Date \_\_\_\_\_

\_\_\_\_\_

Assignor: Hiroaki SHITAMA

Date \_\_\_\_\_

\_\_\_\_\_

Assignor: Nobuyuki TAKAKURA

**ASSIGNMENT**

**WHEREAS, I/We**

(1) Maiko HAMADA of c/o MITSUBISHI TANABE PHARMA CORPORATION,  
3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan,

(2) Yuki ARAI of c/o MITSUBISHI TANABE PHARMA CORPORATION, 3-2-10,  
Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan,

(3) Shuhei YAMAKOSHI of c/o MITSUBISHI TANABE PHARMA  
CORPORATION, 3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan,

(4) Hiroko WADA of c/o MITSUBISHI TANABE PHARMA CORPORATION, 3-2-  
10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan,

(5) Kazufumi OTSUKI of c/o MITSUBISHI TANABE PHARMA CORPORATION,  
3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan,

(6) Hiroaki SHITAMA of c/o MITSUBISHI TANABE PHARMA CORPORATION,  
3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan, and

(7) Nobuyuki TAKAKURA of c/o OSAKA UNIVERSITY, 1-1, Yamadaoka, Suita-  
shi, Osaka 565-0871 Japan,

hereinafter referred to as Assignor, have invented a certain invention entitled:

**NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE**

for which invention an application (provisional or non-provisional) for a U.S. patent was filed  
on November 3, 2021, under U.S. Application No. 17/518,212, and

**WHEREAS,**

MITSUBISHI TANABE PHARMA CORPORATION, 3-2-10, Dosho-machi, Chuo-  
ku, Osaka-shi, Osaka 541-8505 Japan, and

OSAKA UNIVERSITY, of 1-1, Yamadaoka, Suita-shi, Osaka 565-0871 Japan,

hereinafter referred to as Assignee, is desirous of acquiring the entire U.S. right, title,  
and interest of Assignor in, to, and under the invention and the referenced International Patent  
Application, including the entire right, title, and interest of Assignor in, to, and under the U.S.  
national phase thereof, filed on November 3, 2021 as U.S. Patent Application No. 17/518,212,

**NOW, THEREFORE,** for good and valuable consideration, the receipt and sufficiency of  
which is hereby acknowledged,

Assignor assigns and transfers to Assignee the entire U.S. right, title, and interest of Assignor in, to, and under the invention, the referenced International Patent Application and U.S. national phase thereof, and other such U.S. patent applications (e.g., continuations, continuations-in-part, divisionals, reissues, and reexaminations) that may be filed in the U.S. with a claim of priority to the referenced International Patent Application and/or the U.S. national phase application thereof, as well as U.S. patents that may issue thereon and that may be modified as the result of applicable procedures (e.g., supplemental examinations, ex parte reexaminations, inter partes reexaminations, inter partes reviews, and post-grant reviews),

Assignor conveys to the Assignee the right to make applications in Assignee's own behalf for protection of the invention in the U.S. and to claim priority in the U.S. to the aforementioned patent applications and any priority documents referenced therein under the Patent Cooperation Treaty, the Paris Convention, and any other international arrangements,

Assignor will not execute any writing or do any act conflicting with the terms of this assignment,

Assignor will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to pursue the U.S. patent applications identified herein, including, but not limited to, rendering all necessary assistance in making applications for and obtaining patents that may issue thereon in the U.S. on the invention, and in enforcing any rights accruing as a result of such U.S. applications or patents, by, for example, executing statements and other affidavits,

Assignor and Assignee agree the terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,

Assignor authorizes Assignee to insert in this assignment the number and filing date of the U.S. patent application if the number and filing date of the U.S. patent application are not recited herein at the time of execution of this assignment by any or all of the parties hereto,

Assignor and Assignee agree that U.S. law governs this assignment, and

Assignee acknowledges and accepts this assignment.

**IN WITNESS WHEREOF**, Assignor has hereunder set his/her hand on the date shown below.

Date \_\_\_\_\_

Assignor: Maiko HAMADA

Assignment

Attorney Docket No. 758140  
Client Reference No. 203636

Date \_\_\_\_\_

Assignor: Yuki ARAI

Date 2021/11/24

Shuhei Yamakoshi

Assignor: Shuhei YAMAKOSHI

Date \_\_\_\_\_

Assignor: Hiroko WADA

Date \_\_\_\_\_

Assignor: Kazufumi OTSUKI

Date \_\_\_\_\_

Assignor: Hiroaki SHITAMA

Date \_\_\_\_\_

Assignor: Nobuyuki TAKAKURA

**ASSIGNMENT**

**WHEREAS, I/We**

(1) Maiko HAMADA of c/o MITSUBISHI TANABE PHARMA CORPORATION,  
3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan,

(2) Yuki ARAI of c/o MITSUBISHI TANABE PHARMA CORPORATION, 3-2-10,  
Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan,

(3) Shuhei YAMAKOSHI of c/o MITSUBISHI TANABE PHARMA  
CORPORATION, 3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan,

(4) Hiroko WADA of c/o MITSUBISHI TANABE PHARMA CORPORATION, 3-2-  
10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan,

(5) Kazufumi OTSUKI of c/o MITSUBISHI TANABE PHARMA CORPORATION,  
3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan,

(6) Hiroaki SHITAMA of c/o MITSUBISHI TANABE PHARMA CORPORATION,  
3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan, and

(7) Nobuyuki TAKAKURA of c/o OSAKA UNIVERSITY, 1-1, Yamadaoka, Suita-  
shi, Osaka 565-0871 Japan,

hereinafter referred to as Assignor, have invented a certain invention entitled:

**NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE**

for which invention an application (provisional or non-provisional) for a U.S. patent was filed  
on November 3, 2021, under U.S. Application No. 17/518,212, and

**WHEREAS,**

MITSUBISHI TANABE PHARMA CORPORATION, 3-2-10, Dosho-machi, Chuo-  
ku, Osaka-shi, Osaka 541-8505 Japan, and

OSAKA UNIVERSITY, of 1-1, Yamadaoka, Suita-shi, Osaka 565-0871 Japan,

hereinafter referred to as Assignee, is desirous of acquiring the entire U.S. right, title,  
and interest of Assignor in, to, and under the invention and the referenced International Patent  
Application, including the entire right, title, and interest of Assignor in, to, and under the U.S.  
national phase thereof, filed on November 3, 2021 as U.S. Patent Application No. 17/518,212,

**NOW, THEREFORE,** for good and valuable consideration, the receipt and sufficiency of  
which is hereby acknowledged,

Assignor assigns and transfers to Assignee the entire U.S. right, title, and interest of Assignor in, to, and under the invention, the referenced International Patent Application and U.S. national phase thereof, and other such U.S. patent applications (e.g., continuations, continuations-in-part, divisionals, reissues, and reexaminations) that may be filed in the U.S. with a claim of priority to the referenced International Patent Application and/or the U.S. national phase application thereof, as well as U.S. patents that may issue thereon and that may be modified as the result of applicable procedures (e.g., supplemental examinations, ex parte reexaminations, inter partes reexaminations, inter partes reviews, and post-grant reviews),

Assignor conveys to the Assignee the right to make applications in Assignee's own behalf for protection of the invention in the U.S. and to claim priority in the U.S. to the aforementioned patent applications and any priority documents referenced therein under the Patent Cooperation Treaty, the Paris Convention, and any other international arrangements,

Assignor will not execute any writing or do any act conflicting with the terms of this assignment,

Assignor will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to pursue the U.S. patent applications identified herein, including, but not limited to, rendering all necessary assistance in making applications for and obtaining patents that may issue thereon in the U.S. on the invention, and in enforcing any rights accruing as a result of such U.S. applications or patents, by, for example, executing statements and other affidavits,

Assignor and Assignee agree the terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,

Assignor authorizes Assignee to insert in this assignment the number and filing date of the U.S. patent application if the number and filing date of the U.S. patent application are not recited herein at the time of execution of this assignment by any or all of the parties hereto,

Assignor and Assignee agree that U.S. law governs this assignment, and

Assignee acknowledges and accepts this assignment.

**IN WITNESS WHEREOF**, Assignor has hereunder set his/her hand on the date shown below.

Date \_\_\_\_\_

Assignor: Maiko HAMADA

Assignment

Attorney Docket No. 758140

Client Reference No. 203636

Date \_\_\_\_\_

Assignor: Yuki ARAI

Date \_\_\_\_\_

Assignor: Shuhei YAMAKOSHI

Date 2021 / 11 / 24

Hiroko WADA

Assignor: Hiroko WADA

Date 2021 / 11 / 18

Kazufumi OTSUKI

Assignor: Kazufumi OTSUKI

Date 2021 / 11 / 18

Hiroaki SHITAMA

Assignor: Hiroaki SHITAMA

Date \_\_\_\_\_

Assignor: Nobuyuki TAKAKURA

**ASSIGNMENT**

**WHEREAS, I/We**

(1) Maiko HAMADA of c/o MITSUBISHI TANABE PHARMA CORPORATION,  
3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan,

(2) Yuki ARAI of c/o MITSUBISHI TANABE PHARMA CORPORATION, 3-2-10,  
Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan,

(3) Shuhei YAMAKOSHI of c/o MITSUBISHI TANABE PHARMA  
CORPORATION, 3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan,

(4) Hiroko WADA of c/o MITSUBISHI TANABE PHARMA CORPORATION, 3-2-  
10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan,

(5) Kazufumi OTSUKI of c/o MITSUBISHI TANABE PHARMA CORPORATION,  
3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan,

(6) Hiroaki SHITAMA of c/o MITSUBISHI TANABE PHARMA CORPORATION,  
3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan, and

(7) Nobuyuki TAKAKURA of c/o OSAKA UNIVERSITY, 1-1, Yamadaoka, Suita-  
shi, Osaka 565-0871 Japan,

hereinafter referred to as Assignor, have invented a certain invention entitled:

**NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE**

for which invention an application (provisional or non-provisional) for a U.S. patent was filed  
on November 3, 2021, under U.S. Application No. 17/518,212, and

**WHEREAS,**

MITSUBISHI TANABE PHARMA CORPORATION, 3-2-10, Dosho-machi, Chuo-  
ku, Osaka-shi, Osaka 541-8505 Japan, and

OSAKA UNIVERSITY, of 1-1, Yamadaoka, Suita-shi, Osaka 565-0871 Japan,

hereinafter referred to as Assignee, is desirous of acquiring the entire U.S. right, title,  
and interest of Assignor in, to, and under the invention and the referenced International Patent  
Application, including the entire right, title, and interest of Assignor in, to, and under the U.S.  
national phase thereof, filed on November 3, 2021 as U.S. Patent Application No. 17/518,212,

**NOW, THEREFORE,** for good and valuable consideration, the receipt and sufficiency of  
which is hereby acknowledged,

Assignor assigns and transfers to Assignee the entire U.S. right, title, and interest of Assignor in, to, and under the invention, the referenced International Patent Application and U.S. national phase thereof, and other such U.S. patent applications (e.g., continuations, continuations-in-part, divisionals, reissues, and reexaminations) that may be filed in the U.S. with a claim of priority to the referenced International Patent Application and/or the U.S. national phase application thereof, as well as U.S. patents that may issue thereon and that may be modified as the result of applicable procedures (e.g., supplemental examinations, ex parte reexaminations, inter partes reexaminations, inter partes reviews, and post-grant reviews),

Assignor conveys to the Assignee the right to make applications in Assignee's own behalf for protection of the invention in the U.S. and to claim priority in the U.S. to the aforementioned patent applications and any priority documents referenced therein under the Patent Cooperation Treaty, the Paris Convention, and any other international arrangements,

Assignor will not execute any writing or do any act conflicting with the terms of this assignment,

Assignor will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to pursue the U.S. patent applications identified herein, including, but not limited to, rendering all necessary assistance in making applications for and obtaining patents that may issue thereon in the U.S. on the invention, and in enforcing any rights accruing as a result of such U.S. applications or patents, by, for example, executing statements and other affidavits,

Assignor and Assignee agree the terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,

Assignor authorizes Assignee to insert in this assignment the number and filing date of the U.S. patent application if the number and filing date of the U.S. patent application are not recited herein at the time of execution of this assignment by any or all of the parties hereto,

Assignor and Assignee agree that U.S. law governs this assignment, and

Assignee acknowledges and accepts this assignment.

**IN WITNESS WHEREOF**, Assignor has hereunder set his/her hand on the date shown below.

Date \_\_\_\_\_

Assignor: Maiko HAMADA